Development of novel therapeutic strategies that target HIF-1 - PubMed (original) (raw)
Review
Development of novel therapeutic strategies that target HIF-1
Gregg L Semenza. Expert Opin Ther Targets. 2006 Apr.
Abstract
Activity of hypoxia-inducible factor 1 (HIF-1) is increased in human cancers as a result of the physiological induction of HIF-1alpha in response to intratumoural hypoxia and as a result of genetic alterations that activate oncogenes and inactivate tumour suppressor genes. In many cancer types, increased HIF-1alpha expression is associated with increased risk of patient mortality. HIF-1 plays important roles in every major aspect of cancer biology through the transcriptional regulation of hundreds of genes. The efficacy of many novel anticancer agents that target signal transduction pathways may be due in part to their indirect inhibition of HIF-1. Several novel compounds with anticancer activity have been shown to inhibit HIF-1 and may be useful as components of individualised multidrug therapeutic regimens chosen based on molecular analyses of tumour biopsies.
Similar articles
- Role of hypoxia-inducible factor-1alpha as a cancer therapy target.
Patiar S, Harris AL. Patiar S, et al. Endocr Relat Cancer. 2006 Dec;13 Suppl 1:S61-75. doi: 10.1677/erc.1.01290. Endocr Relat Cancer. 2006. PMID: 17259560 Review. - Current insights and future perspectives of hypoxia-inducible factor-targeted therapy in cancer.
Ajith TA. Ajith TA. J Basic Clin Physiol Pharmacol. 2018 Dec 19;30(1):11-18. doi: 10.1515/jbcpp-2017-0167. J Basic Clin Physiol Pharmacol. 2018. PMID: 30260792 Review. - Hypoxia-inducible factor-1 as a therapeutic target in cancer.
Tang CM, Yu J. Tang CM, et al. J Gastroenterol Hepatol. 2013 Mar;28(3):401-5. doi: 10.1111/jgh.12038. J Gastroenterol Hepatol. 2013. PMID: 23173651 Review. - Kamebakaurin inhibits the expression of hypoxia-inducible factor-1α and its target genes to confer antitumor activity.
Wang KS, Ma J, Mi C, Li J, Lee JJ, Jin X. Wang KS, et al. Oncol Rep. 2016 Apr;35(4):2045-52. doi: 10.3892/or.2016.4576. Epub 2016 Jan 19. Oncol Rep. 2016. PMID: 26781327 - Targeting the hypoxia-inducible factor (HIF) pathway in cancer.
Poon E, Harris AL, Ashcroft M. Poon E, et al. Expert Rev Mol Med. 2009 Aug 27;11:e26. doi: 10.1017/S1462399409001173. Expert Rev Mol Med. 2009. PMID: 19709449 Review.
Cited by
- Transcriptional regulation and post-translational modifications in the glycolytic pathway for targeted cancer therapy.
Ni X, Lu CP, Xu GQ, Ma JJ. Ni X, et al. Acta Pharmacol Sin. 2024 Aug;45(8):1533-1555. doi: 10.1038/s41401-024-01264-1. Epub 2024 Apr 15. Acta Pharmacol Sin. 2024. PMID: 38622288 Review. - The Role of Imaging Biomarkers to Guide Pharmacological Interventions Targeting Tumor Hypoxia.
Gallez B. Gallez B. Front Pharmacol. 2022 Jul 15;13:853568. doi: 10.3389/fphar.2022.853568. eCollection 2022. Front Pharmacol. 2022. PMID: 35910347 Free PMC article. Review. - Novel evidence for oncogenic piRNA-823 as a promising prognostic biomarker and a potential therapeutic target in colorectal cancer.
Feng J, Yang M, Wei Q, Song F, Zhang Y, Wang X, Liu B, Li J. Feng J, et al. J Cell Mol Med. 2020 Aug;24(16):9028-9040. doi: 10.1111/jcmm.15537. Epub 2020 Jun 28. J Cell Mol Med. 2020. PMID: 32596991 Free PMC article. - Knockdown of Hypoxia-Inducible Factor 1α Improved the Efficacy of Low-Dose Metronomic Chemotherapy of Paclitaxel in Human Colon Cancer Xenografts.
Zhang M, Chen C, Su F, Huang Z, Li X, Li X. Zhang M, et al. Technol Cancer Res Treat. 2017 Oct;16(5):609-619. doi: 10.1177/1533034616665720. Epub 2016 Aug 29. Technol Cancer Res Treat. 2017. PMID: 27573201 Free PMC article. - Baseline [(18)F]FMISO μPET as a Predictive Biomarker for Response to HIF-1α Inhibition Combined with 5-FU Chemotherapy in a Human Colorectal Cancer Xenograft Model.
De Bruycker S, Vangestel C, Van den Wyngaert T, Wyffels L, Wouters A, Pauwels P, Staelens S, Stroobants S. De Bruycker S, et al. Mol Imaging Biol. 2016 Aug;18(4):606-16. doi: 10.1007/s11307-015-0926-5. Mol Imaging Biol. 2016. PMID: 26728163